Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Table 1

Comparison of the clinical characteristics of responders and nonresponders to IFX after 1 year of treatment of CD patients.

Characteristics	CD patients		value
	Responders	Nonresponders
Number	89	14
Age, mean ± SD (years)	35.4 ± 12.9	37.8 ± 10.3	0.368
Male/female (%)	50/39 (56.2/43.8)	9/5 (64.3/35.7)	0.773
Smoking (%)	17 (19.1)	5 (35.7)	0.172
Concomitant use of immunomodulators (%)	20 (22.5)	8 (57.1)	0.007
Colonic location (%)
Ilium	16 (18.0)	2 (14.3)	1.000
Colon	17 (19.1)	3 (21.4)	1.000
Ileocolon	56 (62.9)	9 (64.3)	1.000
Disease behavior (%)
Nonstricturing/penetrating	43 (48.3)	5 (35.7)	0.409
Stricturing	37 (41.6)	3 (21.4)	0.238
Penetrating	18 (20.2)	8 (57.1)	0.006

Classification according to Montreal Classification for CD.
IFX: infliximab; CD: Crohn’s disease; SD: standard deviation.